Výsledky vyhledávání - "Mary J. Timson"

Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models

Publikováno v: Cancer Research. 83:4045-4045

Background: Mutations in the RAS/MAPK pathway are a frequent driver of cancer, with oncogenic RAS or RAF mutations occurring in >30% of all cancers. First generation BRAF inhibitors are approved for use for tumors with Class I BRAF mutations (V600X).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ebf3a2336f0156e37e4810fe4bbdbdd5
https://doi.org/10.1158/1538-7445.am2023-4045

Zobrazit plný text záznamu

Abstract 4872: DCC-3116, a first-in-class selective ULK1/2 inhibitor of autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models

Autor: Madhumita Bogdan, Mary J. Timson, Hikmat Al-Hashimi, Bryan D. Smith, Daniel L. Flynn

Publikováno v: Cancer Research. 83:4872-4872

Background: Cancer cells activate autophagy as an adaptive stress response (ASR) mechanism to therapies targeting the RTK/RAS/MAPK/PI3K pathways, limiting antitumor response. Autophagy is initiated through ULK1/2 kinases and is triggered by inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c8e970a73387ae450ffd6ba6ca7d728
https://doi.org/10.1158/1538-7445.am2023-4872

Zobrazit plný text záznamu

Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models

Autor: Martin McMahon, Madhumita Bogdan, Mary J. Timson, Hikmat Al-Hashimi, Phaedra Ghazi, Yu Zhan, Bryan D. Smith, Conan G. Kinsey, Daniel L. Flynn

Publikováno v: Cancer Research. 82:3600-3600

Mutationally-activated RAS oncoproteins are detected in approximately 19% of newly diagnosed human cancers and have been targets for drug discovery for over 40 years. Recently, the FDA approved sotorasib, a covalent inhibitor of KRASG12C, for the tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e88168da9ce8a7ac67b9a4b2624c45ba
https://doi.org/10.1158/1538-7445.am2022-3600

Zobrazit plný text záznamu

Abstract P084: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models

Autor: Madhumita Bogdan, Mary J. Timson, Hikmat Al-Hashimi, Yu Zhan, Bryan D. Smith, Daniel L. Flynn

Publikováno v: Molecular Cancer Therapeutics. 20:P084-P084

Background: Activating mutations in EGFR have been reported in ~30% of patients with non-small cell lung cancer (NSCLC). Three generations of small molecule EGFR kinase inhibitors have been approved by the FDA to treat these patients, however, multip

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3610e4b6b0a7d12b93c45373bc603725
https://doi.org/10.1158/1535-7163.targ-21-p084

Zobrazit plný text záznamu

Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers

Publikováno v: Molecular Cancer Therapeutics. 18:B129-B129

Background: Cancer cells activate autophagy, a catabolic process to resupply nutrients and recycle damaged organelles, in order to survive stresses such as limited nutrients and hypoxia, or chemotherapy treatments. RAS mutant cancers, in particular,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5054904b7c6bc718908e801bc3f9ad2b
https://doi.org/10.1158/1535-7163.targ-19-b129

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání